Kiora Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.1M
- Price
- $2.50
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.19%
- Volume
- 20.2K
About
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Quick stats
Shares outstanding4.4M
Computed float4.3M
Float / shares96.9%
Cash runway (months)17.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001372514
Websitehttps://www.kiorapharma.com
AI Summary
AI-generated1/7
minorbullishexecutive change
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Kiora Pharmaceuticals appointed Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs, adding more than 20 years of ophthalmic drug development experience spanning Phase 1 through Phase 4 trials.
Lane joins from Ora, Inc., an ophthalmology-focused CRO, where he was Chief Scientific Officer and oversaw clinical operations and regulatory strategy for more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies supporting three NDA submissions and one BLA submission.
At Kiora, Lane's responsibilities cover U.S. and global registration studies for the current pipeline, supporting KIO-301 in retinitis pigmentosa and other inherited retinal diseases as needed by partners, and advancing potential future assets such as KIO-104 for macular edema.